Brief: Monte Rosa Therapeutics Announces First Development Candidate And Reports Q3 2021 Financial Results
10/11/2021 12:41
Nov 10 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FIRST DEVELOPMENT
CANDIDATE
AND REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND BUSINESS
UPDATES
* MONTE ROSA THERAPEUTICS INC - EXPECTS ITS CASH AND CASH
EQUIVALENTS, INCLUDING AGGREGATE NET PROCEEDS FROM IPO, WILL BE
SUFFICIENT TO FUND PLANNED OPERATIONS AND CAPITAL EXPENDITURES
INTO LATE 2024
* MONTE ROSA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.43
Source text for Eikon: ID:nGNX9WlL8n
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million